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Abstract
FOXO1 is involved in glucocorticoid- and sepsis-induced muscle wasting, in part reflecting regulation of atrogin-1 and
MuRF1. Mechanisms influencing FOXO1 expression in muscle wasting are poorly understood. We hypothesized that the
transcription factor peroxisome proliferator-activated receptor b/d (PPARb/d) upregulates muscle FOXO1 expression and
activity with a downstream upregulation of atrogin-1 and MuRF1 expression during sepsis and glucocorticoid treatment
and that inhibition of PPARb/d activity can prevent muscle wasting. We found that activation of PPARb/d in cultured
myotubes increased FOXO1 activity, atrogin-1 and MuRF1 expression, protein degradation and myotube atrophy.
Treatment of myotubes with dexamethasone increased PPARb/d expression and activity. Dexamethasone-induced FOXO1
activation and atrogin-1 and MuRF1 expression, protein degradation, and myotube atrophy were inhibited by PPARb/d
blocker or siRNA. Importantly, muscle wasting induced in rats by dexamethasone or sepsis was prevented by treatment with
a PPARb/d inhibitor. The present results suggest that PPARb/d regulates FOXO1 activation in glucocorticoid- and sepsis-
induced muscle wasting and that treatment with a PPARb/d inhibitor may ameliorate loss of muscle mass in these
conditions.
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Introduction
Muscle wasting caused by sepsis and high levels of
glucocorticoids is characterized by increased expression of the
ubiquitin ligases atrogin-1 and MuRF1 and stimulated ubiqui-
tin-proteasome-dependent protein breakdown [1–3]. Atrogin-1
and MuRF1 were discovered approximately 10 years ago [4,5]
and are involved in the regulation of muscle mass in various
catabolic conditions [6]. Their activity accounts for the
specificity with regards to protein substrates that are ubiquiti-
nated and degraded by the proteasome [4,5]. Although the
expression and activity of atrogin-1 and MuRF1 are regulated
by multiple mechanisms [7], studies suggest that Forkhead box
O (FOXO) transcription factors, in particular FOXO1, play a
pivotal role in the regulation of atrogin-1 and MuRF1
expression in various muscle atrophy-related conditions, includ-
ing sepsis and glucocorticoid treatment [3,8–13]. FOXO-
dependent gene activation can be regulated by increased overall
expression of the transcription factors and by posttranslational
modifications, including phosphorylation and acetylation [14–
17]. The important role of FOXO transcription factors in the
regulation of muscle mass is illustrated by their involvement not
only in the regulation of atrogin-1 and MuRF1 expression and
ubiquitin-proteasome-dependent proteolysis [10–13] but in the
regulation of autophagy-lysosmal protein degradation as well
[18,19]. Understanding mechanisms regulating FOXO1 expres-
sion and activity during muscle wasting, therefore, has
important clinical and translational implications.
Despite the important role of FOXO transcription factors in
modulating muscle mass, the upstream regulation of the expres-
sion and activity of these transcription factors as well as their
downstream influence on atrogin-1 and MuRF1 expression are
not completely understood. In recent experiments, Nahle et al.
[20] found evidence that FOXO1 expression and activity are
regulated, at least in part, by the transcription factor PPARb/d.
PPARb/d is a member of the PPAR transcription factor family
[21,22]. Members of this family participate in the regulation of
genes involved in protein, carbohydrate, and lipid metabolism in
multiple cell types and tissues [21–25]. In addition to PPARb/d,
PPARa is also expressed in skeletal muscle where it is involved in
the regulation of lipid metabolism [26]. In the study by Nahle
et al. [20], fasting-induced upregulation of FOXO1 expression in
heart muscle and diaphragm was blunted in PPARb/d -deficient
mice. In addition, PPARb/d overexpression induced a robust
increase in FOXO1 expression in cultured C2C12 muscle cells.
Furthermore, analysis of the FOXO1 gene revealed PPAR
response elements in the FOXO1 promoter region and overex-
pression of PPARb/d or pharmacological activation of PPARb/d
with GW0742 transactivated the FOXO1 gene. In the same study
[20], PPARb/d -induced activation of FOXO1 stimulated
pyruvate dehydrogenase kinase 4 (PDK4) and suppressed glucose
oxidation but other downstream targets of FOXO1 were not
investigated. Although it is clear from the study by Nahle et al.
[20] that FOXO1 expression is regulated by PPARb/d, it is not
known if PPARb/d is involved in the regulation of atrogin-1,
MuRF1, and muscle mass in catabolic conditions. This is
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factors in addition to FOXO transcription factors [7]. Important-
ly, it is also not known if inhibition of PPARb/d can prevent
sepsis- and glucocorticoid-induced muscle wasting.
Some evidence suggesting a role of PPARb/d in the regulation
of atrogin-1 and MuRF1 expression was reported by Constantin
et al. [27]. In that study, treatment of rats with the PPARb/d
agonist GW610742 resulted in increased atrogin-1 and MuRF1
mRNA and protein levels in soleus muscles. The interpretation of
those results, however, is complicated for several reasons. First, no
evidence of muscle wasting was found in the GW610742-treated
rats. Muscle weight was not reported but body weight and muscle
protein and DNA concentrations were not affected in the PPARb/
d agonist-treated rats suggesting that muscle wasting was not
induced in those experiments. Second, although muscle protein
degradation rates were not determined, the 20S proteaosme
chymotrypsin-like enzyme activity was unaffected by the PPARb/
d agonist. Third, PPARb/d activity was not measured and it is not
known if the treatment with GW610742 actually resulted in
increased PPARb/d activity. Finally, studies were performed in
the red, slow-twitch soleus muscle and the influence of GW610742
on atrogin-1 and MuRF1 expression in white, fast-twitch muscle
was not investigated. This is important because the influence of
sepsis, glucocorticoids, as well as other catabolic conditions, is
particularly pronounced in fast-twitch skeletal muscle [28].
A study by Fuster et al. [29] provided additional evidence that
PPARb/d may be involved in muscle wasting. In that study,
PPARb/d mRNA levels were increased in skeletal muscle of
tumor bearing rats, but although an association was found
between increased expression of PPARb/d and loss of muscle
mass, no mechanistic studies were performed testing the role of
PPARb/d in cancer-induced muscle wasting. Also, the study by
Fuster et al. [29] was focused on genes involved in fatty acid
transport activation and oxidation and the relationship between
PPARb/d and FOXO1, atrogin-1, and MuRF1 expression was
not examined. In addition, it is not known from the study by
Fuster et al. [29] if the increased mRNA levels for PPARb/d were
associated with increased PPARb/d activity and whether inhibi-
tion of PPARb/d activity could rescue muscle from the catabolic
effects of cancer cachexia.
Thus, the involvement of PPARb/d in muscle wasting and in
the regulation of FOXO1, atrogin-1, and MuRF1 in catabolic
muscle is incompletely understood at present. A better under-
standing of the role of PPARb/d in muscle wasting could have
important clinical implications since evidence of PPARb/d -
regulated expression of FOXO1, atrogin-1, and MuRF1 may
make PPARb/d an important target for the prevention and
treatment of muscle wasting. Here, we tested the hypotheses that
FOXO1 activation and loss of muscle mass induced by
glucocorticoids and sepsis is regulated by PPARb/d and that
inhibition of PPARb/d activity can prevent muscle wasting in
these conditions. Of note, although the potential relationship
between PPARb/d and FOXO1, atrogin-1, and MuRF1 was
examined in previous reports [20,27,29], the present study is
important because it provides novel information about the
mechanistic link between PPARb/d and sepsis- and glucocorti-
coid-induced muscle wasting as well as insight into the therapeutic
implications of PPARb/d inhibition in these conditions.
Materials and Methods
Experiments in Cultured L6 Myotubes
L6 rat skeletal muscle cells (American Type Culture Collection,
Manassas, VA, USA) were maintained and cultured as described
in detail recently [30,31] In short, L6 muscle cells were grown in
Dulbeco’s Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/
ml streptomycin in 10% CO2 atmosphere at 37uC. When cells
reached approximately 80% confluence, they were removed by
trypsinization (0.25% trypsin in phosphate buffered saline, PBS)
and seeded into 6- or 12-multiwell or 10-cm culture plates in the
presence of 10% FBS until they reached approximately 70%
confluence, at which time the medium was replaced with DMEM
containing 2% FBS for induction of differentiation into myotubes.
During this time (5–7 days), the myoblasts fused to form elongated,
multinucleated myotubes. When myotubes had formed, cytosine
arabinoside (10 mM) was added to the culture medium for 48 h in
order to remove any remaining dividing myoblasts. In different
experiments, myotubes were treated for 24 h with 0.1 mM of the
PPARb/d agonist GW0742 (Sigma–Aldrich, St. Louis, MO,
USA), 0.1 mM of the PPARb/d antagonist GSK0660 (Tocris
Bioscience, Ellisville, MI, USA), 1 mM dexamethasone (Sigma–
Aldrich), or 10 mM of RU38486 (Sigma-Aldrich). Control
myotubes were treated with solvent (0.1% DMSO for GW0742
and 0.1% ethanol for GSK0660, dexamethasone, and RU38486).
The concentration of GW0742 used here was based on a
previous report in which the drug activated PPARb/d-dependent
gene transcription in cultured muscle cells in a dose-dependent
manner with concentrations ranging from 0.04 to 0.12 mM [20].
In previous reports, GSK0660 was used in cell culture experiments
at a concentration of 1 mM [32,33]. Because in our experiments,
GSK0660 at 1 mM showed evidence of cell toxicity (cell rounding
and detachment and activated protein breakdown), we tested the
effects of lower GSK0660 concentrations. Results from those
experiments showed that GSK0660 at a concentration of 0.1 mM
significantly reduced protein degradation in control and dexa-
methasone-treated myotubes whereas 0.05 mM GSK0660 did not
influence myotube protein degradation. A GSK0660 concentra-
tion of 0.1 mM was therefore used in our experiments; this
concentration was validated by its inhibition of GW0742-induced
activation of PPARb/d in cultured myotubes (see Results).
The concentrations of dexamethasone and RU38486 used here
were based on previous reports from our laboratory in which these
drugs stimulated and prevented dexamethasone-induced protein
degradation, respectively, in a dose-dependent manner in cultured
L6 myotubes [30,31,34].
In other experiments, differentiated L6 myotubes were trans-
fected with PPARb/d or FOXO1 siRNA or corresponding
concentrations of non-targeting (scrambled) RNA (Dharmacon
Technologies, Lake Placid, NY, USA). The RNA constructs were
added to the culture medium at a concentration of 165 nM
together with the transfection reagent Lipofectamine RNAiMAX
(Invitrogen, Grand Island, NY, USA). After 5 h, the medium was
changed and the myotubes were cultured for an additional 48 h in
DMEM with 2% FBS in order to allow for continued gene
silencing. In the PPARb/d silencing experiment, myotubes were
then treated for 24 h with 1 mM dexamethasone or solvent (0.1%
ethanol). In the FOXO1 silencing experiment, myotubes were
treated for 24 h with 0.1 mM GW0742 or 0.1% DMSO.
After the different treatments, myotube morphology and
diameter and protein degradation rates were determined as
described in detail [30,31]. In other experiments, mRNA and
protein levels for FOXO1, atrogin-1, MuRF1, and PPARb/d
were determined by real-time PCR and Western blot, respectively
(see below). PPARb/d and FOXO1 activity were determined as
described below.
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Two series of experiments were performed in male Sprague-
Dawley rats (50–60 g bw) to determine the effect of GSK0660 on
muscle wasting. In the first series, rats were treated with
dexamethasone (10 mg/kg ip) or corresponding volume of vehicle.
This protocol for dexamethasone treatment of rats was described
in detail previously and results in increased ubiquitin-proteasome-
dependent muscle proteolysis and increased expression of
FOXO1, atrogin-1, and MuRF1 [12,35–37]. In the second series
of in vivo experiments, sepsis was induced by cecal ligation and
puncture (CLP) as described in detail previously [12,35–39]. Other
rats were sham-operated, i.e., they underwent laparotomy and
manipulation, but no ligation or puncture of the cecum. The septic
model used here was used in several previous studies from our
laboratory and results in a reproducible increase in muscle
proteolysis, expression of FOXO1, atrogin-1, and MuRF1 and loss
of muscle mass [12,35–39]. The model is clinically relevant
because it resembles the situation in patients presenting with septic
peritonitis caused by intraabdominal abscesses and devitalized
tissue. Of note, small growing rats were used in the present study.
Rats of the same size were used in several previous reports in
which we studied sepsis- and glucocorticoid-induced muscle
wasting because they have lower extremity muscles that are thin
enough to allow for in vitro incubation and measurement of
protein turnover rates under physiological conditions [28,35,38].
Rats of the same size were used here to make it possible to
compare the present observations with previous studies. Impor-
tantly, we reported previously that metabolic changes in skeletal
muscle during sepsis induced by CLP were similar in small
growing rats and adult rats [40]. Several metabolic and molecular
changes seen in muscle after CLP in young growing rats are
present in muscle from adult septic patients [41].
Groups of rats were treated with GSK0660 (1 mg/kg ip) or
corresponding volume of vehicle (0.5 ml of 50% ethanol ip) 2 h
before treatment with dexamethasone or induction of sepsis. This
dose of GSK0660 was based on a previous report by Sanchez-Siles
et al [42] and did not induce toxic side-effects in the present study
(see below in Results). In fact, a dose as high as 10 mg/kg was
reported to be safe in mice [42]. Sixteen hours after dexameth-
asone treatment or CLP, extensor digitorum longus (EDL) muscles
were harvested, immediately frozen in liquid nitrogen and stored
at 280uC until analyses were performed as described below. EDL
muscles were studied here because white, fast-twitch skeletal
muscle is particularly sensitive to the effects of catabolic conditions,
including glucocorticoid treatment and sepsis [28,35]. Blood was
drawn by heart puncture for measurement of serum concentra-
tions of the liver enzymes alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) using commercial activity assay
kits (Biovision, Mountain View, CA, USA).
Of note, the in vitro and in vivo experimental models used in
the present study, i.e., dexamethasone-treated myotubes and rats
and sepsis in rats induced by CLP, were employed in multiple
previous reports from our laboratory [12,28,30,31,34–41]. In
those studies, dexamethasone treatment of myotubes or rats and
sepsis in rats resulted in increased protein degradation, loss of
muscle mass, and myotube atrophy. In another study from our
laboratory, electron microscopy provided evidence of sarcomere
disruption, disintegration of Z-disks, and morphological changes of
mitochondria (including swelling and loss of membrane structures)
in skeletal muscle from septic rats [43]. In order to provide further
characterization of our experimental septic model, we performed
an additional study in muscles from sham-operated and septic rats
for morphological analysis. In that experiment, tibialis anterior
muscles (a white fast-twitch skeletal muscle similar to the EDL
muscle) were harvested 16 h after sham-operation or CLP. The
muscles were frozen in pre-cooled isopentane and stored at 280uC
until analysis. Microscopic sections were prepared from the mid
portion of each muscle, frozen sections were immunostained with
laminin, and digital photographs were taken. The cross sectional
area (CSA) was measure for a minimum of 50 fibers per muscle
with one muscle each from 6 sham-operated and 6 septic rats.
Result from this experiment showed histological evidence of
muscle atrophy with the muscle fiber CSA in septic rats being
65612% of the CSA in muscles from sham-operated rats
(p,0.05). Taken together, the observations from our previous
reports and the new results of decreased CSA in muscle from
septic rats provide biochemical, molecular, and histological
evidence that both our in vitro and in vivo models used here are
associated with increased proteolysis and atrophy.
Ethics Statement
All animal experiments were carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals and the National Institutes of Health. The
animal protocols were approved by the Institutional Animal Care
and Use Committee at the Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, USA. All surgeries were
performed under sodium pentobarbital anesthesia, and all efforts
were made to minimize suffering.
Preparation of Total and Nuclear Cell and Muscle Extracts
Total cell and muscle lysates were prepared by homogenizing
the muscles and harvesting the myotubes directly in RIPA buffer
(50 mM Tris–HCl, 150 mM NaCl, 0.5% sodium deoxycholate,
0.1% SDS, and 1% Nonidet P-40) containing Protease Inhibitor
Cocktail Tablets (Roche Applied Science, Indianapolis, IN, USA).
Myotube extracts were briefly sonicated using a Model 100 Sonic
Dismembrator (Fisher Scientific, Asheville, NC, USA). Cell and
muscle extracts were centrifuged at 14,000 g for 10 min at 4uC.
Nuclear extracts were prepared using the NE-PERH Nuclear and
Cytoplasmic Extraction Reagents (Thermo Fisher Scientific)
according to the manufacturer’s instructions. Concentrations of
soluble proteins in the lysates were determined by using the
Bradford Protein Assay Kit (Thermo Fisher Scientific) with bovine
serum albumin as standard. Nuclear extracts and cell and muscle
lysates were stored at 280uC until analyzed.
FOXO1 Activity Determination
FOXO1 DNA binding activity was determined in L6 myotube
nuclear extracts using the Trans AM FKHR Transcription Factor
Assay Kit (Active Motif, Carlsbad, CA, USA). In this assay, a
forkhead box element immobilized onto a 96-well plate is
combined with the nuclear extracts. FOXO transcription factors
contained in the extracts bind to the DNA molecule, and FOXO1
is detected by a specific primary antibody. A horseradish
peroxidase-conjugated secondary antibody is then used for
colorimetric detection in a spectrophotometric plate reader.
PPARb/d Activity Determination
PPARb/d DNA binding activity was determined in L6 myotube
and EDL nuclear extracts using the PPARd Transcription Factor
Assay Kit (Cayman, Ann Arbor, MI, USA). In this assay, a double
stranded consensus sequence containing the peroxisome prolif-
erator response element (PPRE) immobilized onto a 96-well plate
is combined with the nuclear extracts. PPARs contained in the
extracts bind specifically to the PPREs, and PPARb/d is detected
by using a specific primary antibody. A horseradish peroxidase-
PPAR b/d and Muscle Wasting
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detection in a spectrophotometric plate reader.
Real-time PCR
Messenger RNA levels for FOXO1, atrogin-1, MuRF1,
PPARb/d, and PPARa were determined by real-time PCR
performed as described in detail in recent reports from this
laboratory [12,30,31,36,37]. Multiplex RT-PCR with amplifica-
tion of 18S RNA as endogenous control, TaqMan analysis and
subsequent calculations were performed with an ABI Prism 7700
Sequence Detection System (Perkin Elmer, Foster City, CA, USA).
The sequences of the forward, reverse, and double-labeled
oligonucleotides for FOXO1, atrogin-1 and MuRF1 used here
were reported recently [12,30,31,37]. PPARb/d and PPARa
mRNA levels were determined using the ABI TaqMan Gene
Expression Assay (Assay ID: Rn01441087_m1 for PPARb/d and
Assay ID: Rn00566193_m1 for PPARa). Amplification of 18S
RNA was performed in the same reaction tubes as an internal
standard with an alternatively labeled probe (VIC-labeled probe)
to distinguish its product from those derived from FOXO1,
atrogin-1, MuRF1, PPARb/d and PPARa mRNA. Atrogin-1,
MuRF1, FOXO1, PPARb/d and PPARa mRNA concentrations
were normalized to the 18S mRNA levels and were expressed as
arbitrary units (AU).
Western Blotting
Western blotting was performed to determine protein expres-
sion of total FOXO1, p-FOXO1(Ser 256), atrogin-1, MuRF-1,
PPARb/d, and the glucocorticoid receptor (GR). The protocol
used for Western blotting was described in detail [12,30,31,36,37].
The following primary antibodies and the appropriate secondary
antibodies were used: a rabbit polyclonal anti-rat FOXO1
antibody (1:1000, Cell Signaling Technology, Danver, MA,
USA), a rabbit polyclonal anti-rat phospho (Ser 256)-FOXO1
antibody (1:1000, Cell Signaling Technology), a goat anti-human
PPARb/d antibody (1:1000, Novus Biologicals, Littleton, CO,
USA), a rabbit polyclonal anti-mouse atrogin-1 antibody (1:1000;
kindly supplied by Dr. Stewart Lecker, Harvard Medical School,
Boston, MA, USA), a mouse polyclonal anti-rat MuRF1 antibody
(1:1000; kindly supplied by Regeneron Pharmaceuticals, NY,
USA), and a rabbit anti-human GR antibody (1:1000, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). A mouse monoclonal anti-
rat a tubulin antibody (1:5000, Sigma–Aldrich, St. Louis, MO,
USA) was used for loading control when total muscle extracts were
immunoblotted and an anti-rat lamin A/C antibody (1:2000, Cell
Signaling Technology) was used for loading control when nuclear
extracts were analyzed. Immunoreactive protein bands were
detected by using the Western Lightning kit for enhanced
chemiluminescence detection (PerkinElmer Life Sciences) and
analyzed using the public domain Image J program (http://rsb.
info.nih.gov.ezp-prod1.hul.harvard.edu/ij/index.html). The
bands were quantified by densitometry and normalized to the
appropriate loading controls.
Co-immunoprecipitation
Co-immunoprecipitation was performed in order to examine
whether there is a physical interaction between PPARb/d and the
GR. Whole cell lysate proteins from myotubes treated with
dexamethasone or solvent were extracted using Pierce IP Lysis
Buffer (Thermo Scientific, Rockford, IL, USA). This moderate
strength modified RIPA buffer effectively solubilizes cellular
proteins but does not disrupt protein complexes. Protein extracts
(50 mg) were immunoprecipitated with a goat anti-human
PPARb/d antibody (1:1000, Novus Biologicals, Littleton, CO,
USA) using the Catch and Release v2.0 Reversible Immunopre-
cipitation System (Millipore, Billerica, MA, USA) following the
manufacturer’s instructions. Samples were mixed in the spin
columns with the antibody overnight at 4uC. The columns were
then washed three times with wash buffer, and bound proteins
were eluted with 26 SDS sample buffer at 95uC for 5 min and
were subjected to SDS-PAGE using 7.5% gels, followed by
transfer to PVDF membranes. The membranes were blocked with
5% non-fat milk in TTBS buffer and incubated with the following
primary antibodies and the appropriate secondary antibodies: a
rabbit anti-human PPARb/d antibody (1:1000, Santa Cruz
Biotechnology) and a rabbit anti-human GR antibody (1:1000,
Santa Cruz Biotechnology).
In other experiments, levels of acetylated FOXO1 (Ac-FOXO1)
were determined in cultured myotubes or rat EDL muscle by co-
immunoprecipitation performed as described in detail recently
[44]. In short, nuclear proteins (300 mg) were pulled down with an
anti-acetyl lysine antibody (Cell Signaling Technology) followed by
Western blotting using a rabbit polyclonal anti-rat FOXO1
antibody (Cell Signaling Technology).
When Western blotting was performed (alone or as part of co-
immunoprecipitation), representative blots are shown in the upper
panel of each figure with data from quantification shown below as
bars. The blots correspond to the groups shown in the bars and are
shown in the same order as the bars.
Statistics
Results are reported as means 6 SEM. Statistical analysis was
performed by using Student’s t-test or one-way ANOVA followed
by Tukey’s post hoc test as appropriate. p,0.05 was considered
statistically significant.
Results
Activation of PPARb/d Results in FOXO1-dependent
Upregulation of Atrogin-1 and MuRF1 in Cultured
Myotubes
In initial experiments, we tested the effects of the PPARb/d
agonist GW0742 [45] on the expression of FOXO1, atrogin-1 and
MuRF1 in cultured L6 myotubes. GW0742 was found in a recent
study to transactivate the FOXO1 promoter in cultured C2C12
myoblasts but PPARb/d activity was not measured in those
experiments [20]. Here, we found that treatment of L6 myotubes
with GW0742 resulted in an approximately 30% increase in
PPARb/d activity (Figure 1A). This effect of GW0742 was blocked
by the PPARb/d inhibitor GSK0660 [46], supporting the
specificity of GW0742 as a PPARb/d activator. When myotubes
were treated with GW0742, mRNA and protein levels for
FOXO1 increased (Figure 1B) and the increased FOXO1
expression was accompanied by stimulated FOXO1 DNA-binding
activity (Figure 1C). Although reduced phosphorylation is an
important mechanism of activation of FOXO transcription factors
[47], recent studies suggest that in certain catabolic conditions,
such as starvation [8] and sepsis [12], FOXO1 activation is caused
by increased levels of total FOXO1, resulting in reduced p-
FOXO1/FOXO1 ratio (even in the presence of increased p-
FOXO1 levels). To test if a similar mechanism is involved in
GW0742-induced activation of FOXO1, cellular levels of p-
FOXO1(Ser 256) and total FOXO1 were determined. Treatment
of the myotubes with GW0742 resulted in a reduced p-FOXO1/
FOXO1 ratio reflecting a more pronounced increase in total
FOXO1 than in p-FOXO1 levels (Figure 1D). Thus, the increased
FOXO1 activity in GW0742-treated myotubes probably reflected
a net increase in unphosphorylated (activated) FOXO1.
PPAR b/d and Muscle Wasting
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e59726Figure 1. PPARb/d activation upregulates atrogin-1 and MuRF1 expression through a FOXO1-dependent mechanism in L6
myotubes. A) PPARb/d activity in cultured L6 myotubes treated for 24 h with 0.1 mM GW0742 in the absence or presence of 0.1 mM GSK0660.
Results are expressed as percent of control (Ctr). B) FOXO1 mRNA (left panel) and protein levels (right panel) in cultured L6 myotubes after treatment
for 24 h with 0.1 mM GW0742. Representative Western blots are shown in the upper and densitometric quantifications in the lower panel. A/C lamin
was determined for loading control. C) FOXO1 DNA binding activity in control and GW0742-treated myotubes. D) p-FOXO1(Ser 256) and total FOXO1
protein levels (upper panel) and calculated p-FOXO1/FOXO1 ratio in cultured L6 myotubes after treatment for 24 h with 0.1 mM GW0742. The
calculated p-FOXO1/FOXO1 ratio was based on densitometric quantifications of p-FOXO1 and total FOXO1 levels on Western blots. E) Ac-FOXO1
levels in control and GW0742-treated myotubes determined by co-immunoprecipitation. F) Atrogin-1 mRNA and protein levels in cultured L6
myotubes after treatment for 24 h with 0.1 mM GW0742 and in control myotubes. a-Tubulin was determined for loading control. G) MuRF1 mRNA
and protein levels in control and GW0742-treated myotubes. H) GW0742-induced increase in mRNA levels for FOXO1, atrogin-1, and MuRF1 in
myotubes transfected with a non-targeting (NT) or FOXO1 siRNA. Results are means 6 SEM with n=7 or 8/group. *p,0.05 vs control (Ctr) or NT
groups by Student’s t-test (panel B-H) or ANOVA (panel A).
doi:10.1371/journal.pone.0059726.g001
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FOXO1 activity [44,48–50]. We next tested whether GW0742-
induced PPARb/d activation may be associated with increased
acetylation of FOXO1 by measuring myotube levels of Ac-
FOXO1. Treatment of myotubes with GW0742 did not influence
Ac-FOXO1 levels (Figure 1E) suggesting that the GW0742-
induced FOXO1 activation was not regulated by increased
FOXO1 acetylation under the present experimental conditions.
We next examined whether GW0742 would increase the
expression of atrogin-1 and MuRF1. Treatment of the myotubes
with GW0742 resulted in increased mRNA and protein levels for
both atrogin-1 (Figure 1F) and MuRF1 (Figure 1G). To test the
link between increased expression and activity of FOXO1 and
atrogin-1 and MuRF1 expression in GW0742-treated myotubes,
we employed FOXO1 siRNA. Transfection of the myotubes with
FOXO1 siRNA resulted in a robust reduction of the GW0742-
induced increase in FOXO1 expression and a significant (albeit
smaller) inhibition of the GW0742-induced increase in atrogin-1
and MuRF1 expression, suggesting that atrogin-1 and MuRF1
expression in PPARb/d-activated muscle cells is at least in part
regulated by FOXO1 (Figure 1H).
Treatment of Cultured Muscle Cells with the PPARb/d
Agonist GW0742 Increases Protein Degradation and
Induces Myotube Atrophy
Importantly, the GW0742-induced PPARb/d activation was
accompanied by an approximately 35% increase in myotube
protein degradation (Figure 2A) and a 30% reduction of myotube
diameter (Figure 2B and C). Together, results shown in Figure 1
and 2 suggest that GW0742 activates PPARb/d in skeletal muscle
and that this activation results in upregulated expression and
activity of FOXO1 and FOXO1-dependent expression of atrogin-
1 and MuRF1. In addition, results suggest that these effects of
PPARb/d activation are accompanied by stimulated muscle
proteolysis and myotube atrophy.
Treatment of Cultured Myotubes with Dexamethasone
Increases PPARb/d Activity through a Glucocorticoid
Receptor (GR)-dependent Mechanism
In previous studies, treatment of cultured muscle cells with
dexamethasone resulted in upregulated expression of atrogin-1
and MuRF1, increased protein degradation, and atrophy [30,31].
Those were important observations because sepsis-induced muscle
wasting is regulated by glucocorticoids [35,38] and high levels of
glucocorticoids by themselves stimulate muscle proteolysis [2,3].
Thus, dexamethasone-treated cultured myotubes provide a
relevant in vitro model of muscle wasting [31]. Previous reports
suggest that glucocorticoids upregulate the expression and activity
of PPARa and c [51–54] but the influence of glucocorticoids on
PPARb/d expression and activity is not known. Here, we found
that treatment of cultured L6 myotubes with dexamethasone
resulted in an approximately 20% increase in PPARb/d activity
(Figure 3A). This activation did not reflect increased abundance of
PPARb/d since PPARb/d protein levels were unchanged in
dexamethasone-treated myotubes (Figure 3B). Previous studies
suggest that glucocorticoid-induced activation of PPARc reflects
an interaction between PPARc and the GR [54]. It is not known if
the GR plays a similar role in PPARb/d activation. We therefore
tested the role of the GR in dexamethasone-induced PPARb/d
activation in cultured L6 myotubes. When myotubes were treated
with the GR antagonist RU38486 [55], the dexamethasone-
induced activation of PPARb/d was blocked (Figure 3C). Co-
immunoprecipitation provided evidence for increased interaction
between PPARb/d and the GR in dexamethasone-treated
myotubes (Figure 3D). Together, results shown in Figure 3 suggest
that glucocorticoids activate PPARb/d in skeletal muscle cells and
that this effect of glucocorticoids is at least in part regulated by the
GR, and is associated with protein-protein interaction between
PPARb/d and the GR.
The PPARb/d Antagonist GSK0660 Blocks the Catabolic
Effects of Dexamethasone in Cultured Myotubes
Having established that PPARb/d is activated by glucocorti-
coids and that PPARb/d can upregulate the expression and
activity of FOXO1 as well as expression of atrogin-1 and MuRF1,
stimulate protein degradation, and cause muscle cell atrophy, we
next tested whether dexamethasone-induced activation of
FOXO1, expression of atrogin-1 and MuRF1 and protein
degradation can be inhibited by blocking PPARb/d activity.
Two approaches were used to examine this question. First, we
used the PPARb/d antagonist GSK0660 [46]. Treatment of
myotubes with 0.1 mM GSK0660 prevented the dexamethasone-
induced increase in PPARb/d activity (Figure 4A), expression and
activity of FOXO1 (Figure 4B and C) and expression of atrogin-1
and MuRF1 (Figure 4D and E). In addition, dexamethasone-
induced increase in protein degradation (Figure 4F) and myotube
atrophy (Figure 4G) were inhibited by GSK0660. Together, results
shown in Figure 4 suggest that inhibition of PPARb/d activity with
GSK0660 can prevent glucocorticoid-induced FOXO1 activation,
upregulation of atrogin-1 and MuRF1, muscle proteolysis and
atrophy.
Downregulation of PPARb/d Expression with siRNA
Reduces FOXO1 and MuRF1 Expression and Protein
Degradation in Dexamethasone-treated Myotubes
Although GSK0660 has been reported to be specific in its
inhibitory effect on PPARb/d [46] non-specific effects of
GSK0660 have been described as well, for example recruitment
of various transcriptional corepressors [33]. In order to avoid the
potential influence of non-specific effects of GSK0660, a second
approach was used to test whether inhibition of PPARb/d may
prevent dexamethasone-induced catabolic responses in cultured
myotubes. In this experiment, the expression of PPARb/d was
reduced by using PPARb/d siRNA. Transfecting myotubes with
the siRNA construct resulted in an approximately 65% reduction
of PPARb/d mRNA levels (Figure 5A). This effect of PPARb/d
siRNA did not reflect a generalized reduction of gene transcription
since the expression of another PPAR family member, PPARa,
was not influenced by PPARb/d siRNA (Figure 5A). This was an
important observation because both PPARa and PPARb/d are
expressed in skeletal muscle and a significant redundancy in the
regulatory effects of PPARa and PPARb/d has been reported
[26]. PPARb/d protein levels and activity were reduced by
approximately 30% and 60%, respectively, in PPARb/d siRNA-
transfected myotubes (Figure 5B and C). Importantly, downreg-
ulation of PPARb/d expression with siRNA reduced FOXO1 and
MuRF1 expression in dexamethasone-treated myotubes
(Figure 5D and E). Surprisingly, PPARb/d siRNA did not
influence atrogin-1 mRNA levels in dexamethasone-treated myo-
tubes (Figure 5F). This was different from the results observed after
treatment with GSK0660 which resulted in reduced expression of
both atrogin-1 and MuRF1 in dexamethasone-treated myotubes
(see Figure 4D and E). Although we do not have an explanation
for these apparently contradictory results at present, the different
effects of GSK0660 and PPARb/d siRNA with regards to atrogin-
1 expression may reflect non-specific effects of GSK0660 or
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PPARb/d siRNA. Importantly, however, downregulation of
PPARb/d expression with siRNA blocked the dexamethasone-
induced increase in protein degradation (Figure 5G), similar to the
effect of GSK0660 (compare with Figure 4F).
Treatment of Rats with GSK0660 Prevents
Dexamethasone-induced Muscle Wasting
Although the results reported here provide important novel
information regarding the role of PPARb/d in glucocorticoid-
induced muscle atrophy and the effects of PPARb/d inhibition in
dexamethasone-treated myotubes, it is important from a clinical
standpoint to determine whether treatment with a PPARb/d
inhibitor can prevent glucocorticoid-induced muscle wasting
in vivo. In order to address this question, we administered
GSK0660 to dexamethasone-treated rats. The dose of GSK0660
used here (1 mg/kg) was based on a previous report by Sanchez-
Siles et al. [42]. The treatment was well tolerated as suggested by
unchanged liver function tests (Fig. 6A and B) and the absence of
mortality among GSK0660-treated rats. Treatment of rats with
10 mg/kg of dexamethasone resulted in an approximately 75%
increase in PPARb/d activity in skeletal muscle and this effect of
dexamethasone was abolished by GSK0660 (Figure 6C). The dose
of dexamethasone used here was based on previous reports in
Figure 2. The PPARb/d agonist GW0742 increases protein degradation and induces atrophy of cultured L6 myotubes. A) Protein
degradation (% per 24 h) in myotubes treated for 24 h with 0.1 mM GW0742 or vehicle (Ctr). B) Morphology of cultured L6 myotubes after treatment
for 24 h with 0.1 mM GW0742 or vehicle (Ctr). Myotubes were photographed under a phase contrast microscope at 1006magnification. C) Diameter
of cultured myotubes after treatment for 24 h with 0.1 mM GW0742 or vehicle (Ctr). Results are means 6 SEM with n=8/group.*p,0.05 vs control.
doi:10.1371/journal.pone.0059726.g002
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in increased ubiquitin-proteasome-dependent muscle proteolysis
and upregulated expression of FOXO1, atrogin-1, and MuRF1
[35–37], supporting the catabolic effects of glucocorticoids [2,3].
Here we found that treatment with GSK0660 reduced the loss of
body and muscle weight in dexamethasone-treated rats (Figure 6D
and E) suggesting that GSK0660 can prevent glucocorticoid-
induced muscle wasting in vivo. This was further supported by
GSK0660-induced inhibition of FOXO1, atrogin-1 and MuRF1
mRNA and protein levels in dexamethasone-treated rats
(Figure 6F–K). Together, results shown in Figure 6 suggest that
glucocorticoids increase PPARb/d activity in skeletal muscle
in vivo and that inhibition of PPARb/d activity can rescue muscle
from the catabolic effects of glucocorticoids.
Although our experiments in cultured myotubes provided
evidence that increased FOXO1 activity following GW0742-
induced activation of PPARb/d was associated with increased
total FOXO1 levels and reduced p-FOXO1/FOXO1 ratio (see
Figure 1D), it is not known if the same mechanism regulates
dexamethasone-induced FOXO1 activation in vivo and if
PPARb/d is involved. To examine that question, we determined
total FOXO1 and p-FOXO1 levels in EDL muscles of rats treated
with dexamethasone and GSK0660. Treatment of rats with
10 mg/kg of dexamethasone resulted in increased muscle levels of
both total and phosphorylated FOXO1 with the increase in total
FOXO1 being greater than the increase in p-FOXO1, resulting in
a reduced p-FOXO1/FOXO1 ratio (Figure 7A). When rats were
treated with GSK0660, total FOXO1 and p-FOXO1 levels were
reduced in both control and dexamethasone-treated rats. Taken
together, these observations suggest that dexamethasone-induced
FOXO1 activation in vivo is associated with increased total
FOXO1 levels (similar to dexamethasone-induced activation in
cultured myotubes) and that FOXO1 levels are regulated by
PPARb/d activity in both control and dexamethasone-treated
rats.
In recent experiments, we found that treatment of cultured
myotubes with dexamethasone resulted in increased levels of
acetylated FOXO1 [44]. Here, we found that treatment of rats
in vivo with dexamethasone also increased muscle levels of Ac-
FOXO1 (Fig. 7B). Treatment of rats with GSK0660 alone did not
Figure 3. Dexamethasone increases PPARb/d activity in cultured L6 myotubes through a GR-dependent mechanism. A) PPARb/d
activity in myotubes treated for 24 h with 1 mM dexamethasone or vehicle (Ctr). Results are expressed as percent of control. B) PPARb/d protein levels
determined by Western blotting in total cell lysates from control and dexamethasone-treated myotubes. Representative Western blots are shown in
the upper panel and densitometric quantifications in the lower panel. a-Tubulin was determined for loading control. C) PPARb/d activity in control
and dexamethasone-treated myotubes. Myotubes were treated for 24 h with dexamethasone (1 mM) in the absence or presence of 10 mM RU38486.
D) PPARb/d-GR interaction determined by co-immunoprecipitation of myotube proteins extracted from whole cell lysates after treatment of the
myotubes for 24 h with 1 mM dexamethasone or vehicle (Ctr). A PPARb/d antibody was used for pull-down followed by immuno blotting with a GR or
PPARb/d antibody. Representative immunoblots are shown in the upper panel and densitometric quantifications of the upper bands in the
immunoblts are shown in the lower panel. Results were calculated as percent of control and are means 6 SEM with n=7 or 8/group. *p,0.05 vs Ctr
by Student’s t-test (panel A and D) or ANOVA (panel C).
doi:10.1371/journal.pone.0059726.g003
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PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e59726Figure 4. The PPARb/d antagonist GSK0660 blocks the catabolic effects of dexamethasone in cultured L6 myotubes. A) PPARb/d
activity in myotubes treated with or without 1 mM dexamethasone in the absence or presence of 0.1 mM GSK0660. B) FOXO1 protein levels in
myotubes treated as described in panel A. FOXO1 levels were determined by Western blotting of nuclear extracts and A/C lamin levels were
determined as loading controls. C) FOXO1 activity in myotubes treated for 24 h with 1 mM dexamethasone in the absence or presence of 0.1 mM
GSK0660. D) Atrogin-1 and E) MuRF1 mRNA levels in myotubes treated for 24 h with or without 1 mM dexamethasone in the absence or presence of
0.1 mM GSK0660. F) Protein degradation (% per 24 h) in myotubes treated for 24 h with or without 1 mM dexamethasone in the absence or presence
of 0.1 mM GSK0660. G) Diameter of myotubes after treatment for 24 h with or without 1 mM dexamethasone in the absence or presence of 0.1 mM
GSK0660. Results are means 6 SEM with n=7 or 8/group. *p,0.05 vs Ctr/Veh by ANOVA.
doi:10.1371/journal.pone.0059726.g004
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not only prevent the dexamethasone-induced increase in Ac-
FOXO1 levels but reduced the levels below control levels.
Sepsis-induced Muscle Wasting in Rats is Improved by
Treatment with GSK0660
The effects of dexamethasone in cultured myotubes and in rats
were examined in the present study because high levels of
glucocorticoids by themselves induce muscle wasting and because
muscle wasting in several catabolic conditions, including sepsis, is
mediated by glucocorticoids [2,3,35,38,39]. Several previous
reports provided evidence that sepsis is associated with loss of
muscle mass and upregulated expression and activity of FOXO1,
atrogin-1 and MuRF1 [12,36,37,39,56]. In contrast, the influence
of sepsis on muscle PPARb/d activity in skeletal muscle has not
been reported and it is not known if treatment with a PPARb/d
inhibitor can prevent sepsis-induced muscle wasting. Here, we
Figure 5. Downregulation of PPARb/d expression reduces FOXO1 and MuRF1 expression and protein degradation in
dexamethasone-treated myotubes. A) mRNA levels for PPARb/d and PPARa in myotubes transfected with non-targeting (NT) or PPARb/d
siRNA. B) PPARb/d protein levels in myotubes transfected with non-targeting (NT) or PPARb/d siRNA. Representative Western blots are shown in the
upper and densitomtric quantifications in the lower panel. C) PPARb/d activity in myotubes transfected with non-targeting (NT) or PPARb/d siRNA. D-
F) Dexamethasone-induced changes in FOXO1, MuRF1, and atrogin-1 mRNA in myotubes transfected with non-targeting (NT) or PPARb/d siRNA. G)
Protein degradation in myotubes treated for 24 h with or without 1 mM dexamethasone following transfection with non-targeting (NT) or PPARb/d
siRNA. Results are reported as arbitrary units (AU) or percent of control and are means 6 SEM with n=7 or 8/group. *p,0.05 vs appropriate control
group by ANOVA (panel G) or Student’s t-test.
doi:10.1371/journal.pone.0059726.g005
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PLOS ONE | www.plosone.org 10 March 2013 | Volume 8 | Issue 3 | e59726Figure 6. Treatment of rats with GSK0660 prevents dexamethasone-induced muscle wasting. A) and B) Serum ALT and AST levels in
control and dexamethasone-treated (10 mg/kg) rats that were administered vehicle or GSK0660 (1 mg/kg). C) PPARb/d activity in EDL muscles from
control and dexamethasone-treated rats that were administered vehicle or GSK0660. D) Change of body weight in control and dexamethasone-
treated rats that were administered vehicle or GSK0660. E) Muscle weight in control and dexamethasone-treated rats that were administered vehicle
or GSK0660. F-H) mRNA and I-K) protein levels for FOXO1, atrogin-1, and MuRF1 in muscles from control and dexamethasone-treated rats that were
administered vehicle or GSK0660. Results are means 6 SEM with n=8/group. *,0.05 vs appropriate control group; #p,0.05 vs Veh/Dex group by
ANOVA.
doi:10.1371/journal.pone.0059726.g006
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in rats resulted in an approximately 50% increase in PPARb/d
activity in skeletal muscle and this effect of sepsis was blocked by
treatment with GSK0660 (Figure 8A). Importantly, treatment with
GSK0660 reduced sepsis-induced loss of muscle mass (Figure 8B)
and blunted (but did not completely prevent) sepsis-induced
upregulation of FOXO1, atrogin-1 and MuRF1 mRNA
(Figure 8C–E) and protein levels (Figure 8F–H). Taken together,
these results suggest that sepsis-induced muscle wasting is
associated with increased PPARb/d activity and can be improved
by treatment with a PPARb/d inhibitor.
In previous studies, sepsis in rats was associated with increased
expression of the GR in skeletal muscle [57] and sepsis-induced
muscle wasting as well as expression of atrogin-1, MuRF1, and
FOXO1 were prevented by treatment with the glucocorticoid
receptor antagonist RU38486 [12,35,38,39]. In the present study,
the dexamethasone-induced PPARb/d activation in cultured
myotubes was GR-dependent (see Figure 3C). Taken together,
these observations raise the possibility that the effects of GSK0660
in septic rats may reflect prevention of the sepsis-induced increase
in muscle GR levels. To test that possibility, we determined GR
protein levels in EDL muscles from septic rats treated with
GSK0660. As expected [57], GR levels were increased in muscle
from septic rats but this increase was not prevented by GSK0660
(Figure 8I). Therefore, if sepsis-induced PPARb/d activation is
GR-dependent (as suggested by the results in dexamethasone-
treated myotubes, see Figure 3C), it may reflect other mechanisms
than increased GR abundance, for example an increased
interaction between the GR and PPARb/d as suggested by results
in dexamethasone-treated myotubes (See Figure 3D).
Discussion
The present results suggest that the transcription factor
PPARb/d regulates FOXO1 expression in skeletal muscle and
plays an important role in glucocorticoid- and sepsis-induced
muscle wasting. In addition, results suggest that inhibition of
PPARb/d activity can prevent the catabolic effects in skeletal
muscle caused by sepsis and high glucocorticoid levels. The study
is important because it provides novel information about
mechanisms involved in muscle wasting and suggests, for the first
time, that PPARb/d may be a target for prevention of sepsis- and
glucocorticoid-induced muscle wasting. The observations have
significant clinical implications because loss of muscle mass has
multiple severe consequences, including muscle weakness, delayed
ambulation with increased risk for thromboembolic complications
in critical illness, and risk for pulmonary complications and
difficulties weaning patients from mechanical ventilatory support
when respiratory muscles are affected [58–61].
The study by Nahle et al. [20] suggests that PPARb/d
activation in skeletal muscle is at least in part regulated by
increased expression and activity of the fatty acid translocase
CD36 and elevated fatty acid levels. Although those mechanisms
were not investigated in the present report, studies from other
laboratories suggest that the expression and activity of CD36 and
other fatty acid transport proteins (FATPs) as well as fatty acid
accumulation are increased in catabolic muscle [62–65]. In recent
experiments in our laboratory, CD36 expression was increased in
skeletal muscle during sepsis and treatment of cultured myotubes
with dexamethasone resulted in increased expression of CD36 and
FATP1 (unpublished observations). Thus, it is likely that increased
fatty acid transport is involved in PPARb/d activation during
sepsis and glucocorticoid treatment. Importantly, the present study
provides evidence for an additional, novel, mechanism of PPARb/
d activation by showing that glucocorticoids and the GR are
involved in PPARb/d activation in skeletal muscle and that the
role of the GR may reflect the formation of a complex between the
GR and PPARb/d. Because sepsis-induced muscle wasting is
regulated by glucocorticoids and can be prevented by the GR
antagonist RU38486 [35,38,39], it is possible that glucocorticoids
and the GR participate in the activation of PPARb/d during sepsis
as well. Our results in GSK0660-treated septic rats suggest that the
role of the GR in sepsis-induced PPARb/d activation does not
depend on the increased levels of the GR in septic muscle but may
reflect other mechanisms, such as an increased protein-protein
interaction between the GR and PPARb/d as suggested by results
in dexamethasone-treated myotubes. It should be noted that
although the present study and a report by Nie et al. [54] suggest
that a physical interaction between the GR and PPAR transcrip-
tion factors may be a mechanism of glucocorticoid-induced PPAR
Figure 7. Treatment of rats with GSK0660 prevents dexameth-
asone-induced increase in total FOXO1, p-FOXO1, and Ac-
FOXO1. A) p-FOXO1 and total FOXO1 levels in EDL muscles from
control and dexamethasone-treated rats that were administered vehicle
or GSK0660. B) Ac-FOXO1 levels in EDL muscles from the same groups
of rats that were studied in panel A. Results are means 6 SEM with
n=6–8/group. *p,0.05 vs Ctr; #p,0.05 vs corresponding vehicle
group by ANOVA.
doi:10.1371/journal.pone.0059726.g007
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interaction with nuclear coactivators shared by PPAR transcrip-
tion factors and the GR [66–68].
Even though evidence for PPARb/d-regulated FOXO1 ex-
pression in cultured muscle cells was reported previously [20], the
downstream consequences of PPARb/d activation examined in
that report were changes in PDK4 expression and activity and
glucose oxidation. The present study provides the first evidence of
a PPARb/d-FOXO1-atrogin-1/MuRF1 pathway in glucocorti-
coid- and sepsis-induced muscle wasting. Our observations
confirm the central role of FOXO1 in muscle wasting [8–13],
and suggest that inhibition of PPARb/d may prevent loss of
muscle mass in catabolic conditions secondary to inhibition of
FOXO1 expression and activity. The fact that FOXO1, as well as
FOXO3a, regulate not only genes in the ubiquitin-proteasome
proteolytic pathway, such as atrogin-1 and MuRF1 [11,13], but
also genes in the autophagy-lysosomal pathway [18,19], makes
PPARb/d an even more attractive target for prevention of muscle
wasting.
Although reduced phosphorylation is an important mechanism
of FOXO1 activation [47], the present results and previous studies
[8,12] suggest that increased levels of total FOXO1, even in the
Figure 8. Sepsis-induced muscle wasting in rats is improved by treatment with GSK0660. A) PPARb/d activity in EDL muscles from sham-
operated (SH) and septic (CLP) rats treated with vehicle or GSK0660 (1 mg/kg). B) Muscle weight in sham-operated and septic rats treated with
vehicle or GSK0660. C-E) mRNA and F-H) protein levels for FOXO1, atrogin-1, and MuRF1 in muscles from sham-operated and septic rats treated with
vehicle or GSK0660. I) GR protein levels in EDL muscles from sham-operated and septic rats treated with vehicle or GSK0660. Results are means 6
SEM with n=8/group except in panel I where n=4/group. *p,0.05 vs appropriate sham group; #p,0.05 vs Veh/CLP by ANOVA.
doi:10.1371/journal.pone.0059726.g008
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increase in unphosphorylated (activated) FOXO1 as suggested by
a reduced p-FOXO1/FOXO1 ratio. Of note, the present results
suggesting that PPARb/d-induced FOXO1 activation was asso-
ciated with increased abundance of total FOXO1 without
reduction of p-FOXO1 levels do not rule out the possibility that
other posttranslational modifications were involved in the
increased FOXO1 activity. For example, studies suggest that
increased acetylation results in increased FOXO1 activity [48,49]
and in recent studies we found evidence that increased FOXO1
acetylation is involved in the catabolic response to dexamethasone
in cultured myotubes [44,50]. Results in the present study suggest
that PPARb/d activation is not sufficient to increase FOXO1
acetylation (as illustrated in GW0742-treated myotubes). In
contrast, PPARb/d may be involved in glucocorticoid-induced
FOXO1 acetylation as suggested by results from dexamethasone-
treated rats that were administered GSK0660.
The present observation that treatment with GSK0660
reduced, but did not completely prevent, the increase in FOXO1,
atrogin-1, and MuRF1 expression in septic rats, despite normal-
ized PPARb/d activity, probably reflects the influence of
additional transcription factors involved in muscle wasting,
including NF-kB [69–71] and C/EBPb [30,72]. Prevention of
muscle wasting during sepsis and other catabolic conditions will
probably require a multifaceted approach addressing multiple
mechanisms involved in loss of muscle mass. The present study is
important because it provides the first evidence that inhibition of
PPARb/d activity may be an essential component of treatment
aimed at rescuing muscle from the influence of catabolic
conditions.
The present results are apparently contradicted by previous
studies suggesting that PPARb/d activation may be protective,
rather than harmful, in skeletal muscle, for example by increasing
insulin sensitivity [73,74] and by enhancing mitochondrial
biogenesis and function [75–77]. Those observations are pertinent
for the present study because previous reports suggest that sepsis-
and glucocorticoid-induced muscle wasting is associated with
insulin resistance [78,79] and reduced mitochondrial biogenesis
and function [80,81]. Of note, however, some of the potentially
protective effects of PPARb/d are controversial. Thus, evidence of
unaffected [82–84] or even reduced insulin sensitivity [85]
following activation of PPARb/d was reported recently. In other
studies, treatment with a PPARb/d agonist either did not
influence mitochondrial function [27] or resulted in uncoupled
oxidative phosphorylation in isolated muscle mitochondria [86],
changes that are typically associated with increased generation of
oxygen radicals and deleterious effects on mitochondrial function
[87]. Regardless of the influence of PPARb/d on other metabolic
changes accompanying muscle wasting, the present results provide
strong evidence that activation of PPARb/d results in upregulation
of genes in the ubiquitin-proteasome pathway, stimulation of
protein degradation, and atrophy of muscle cells and, importantly,
that inhibition of PPARb/d improves glucocorticoid- and sepsis-
induced muscle wasting.
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